Log In
BCIQ
Print this Print this
 

JRC2-LAMP-vax vaccine (ASP4070)

  Manage Alerts
Collapse Summary General Information
Company Immunomic Therapeutics Inc.
DescriptionPlasmid-based DNA vaccine containing the Cry J1 and Cry J2 plasmids that uses a lysosomal-associated membrane protein (LAMP) antigen targeting sequence to enhance immune response
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationAllergic conjunctivitis
Indication Details Treat rhinoconjunctivitis symptoms caused by allergic reaction to Japanese red cedar pollen
Regulatory Designation
PartnerAstellas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$70.0M

$15.0M

$55.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/30/2015

$70.0M

$15.0M

$55.0M

Get a free BioCentury trial today